$695 | Single User
$1395 | Global License

Physician Views: Sanofi's Lemtrada finally approved in the US – how will neurologists use the multiple sclerosis therapy?
[Lowest Price Guaranteed: $695]

Published by FirstWord Pharma: 25 Nov 2014 | 175 | In Stock
Related Topics: FDA , Lemtrada

Introduction

Scope



Two years after it was first submitted for approval with the FDA, Sanofi's multiple sclerosis treatment Lemtrada was green-lighted for launch in the US earlier this month.


The product featured notably during Sanofi's investor day last week and continues to intrigue, given the combination of its impressive efficacy and notable side-effect profile.


While EU regulators were less cautious in their appraisal of Lemtrada (approving for use in first-line patients if physicians see fit), the FDA approved a label that limits use to the third-line setting.


Patients who see their MS progress beyond two lines of therapy still represent a significant share of the relapsing market, equal to around 50 percent of all patients, noted Sanofi management last week (ViewPoints: Sanofi's Lemtrada flies the flag for patient power; can it carve a niche in the US multiple sclerosis market?).


The French company argues that uptake among European physicians is encouraging (a trend supported by a pre-launch Physician Views poll run by FirstWord last year; Physician Views Poll Results – Sanofi's new multiple sclerosis treatment Lemtrada to be used more widely than expected?), with a lack of significant revenue to date illustrative of the protracted reimbursement processes that are typical of the region. Consensus forecasts sourced from Bloomberg indicate global sales in 2018 of around 5 million.


Puchase Reasons


With these factors in mind, coupled with reportedly strong US patient advocacy support to influence the FDA's assessment of Sanofi's drug, we are polling US based neurologists to ascertain how they expect to prescribe Lemtrada. Specifically we are asking them...


  • To what percentage of patients with relapsing forms of MS would you expect to prescribe Lemtrada 12 months post-launch?

  • Based on your knowledge of the product, in what line of therapy (irrespective of labelling for the drug) do you think use of Lemtrada is best suited?

  • What barrier to usage do you expect Lemtrada's specified use in third-line patients will provide?

  • Would you consider prescribing Lemtrada in an off-label (i.e. earlier than third line) capacity?

  • At peak, to what percentage of relapsing MS patients would you expect to prescribe Lemtrada?
  • Table of Contents
    for Physician Views: Sanofi's Lemtrada finally approved in the US – how will neurologists use the multiple sclerosis therapy?

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    175 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Sanofi's Lemtrada finally approved in the US – how will neurologists use the multiple sclerosis therapy? | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...